Exhibit 99.2
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data, unaudited)
Three Months Ended March 31, | ||||||||
2014 | 2013 | |||||||
Revenue | $ | 133,832 | $ | 112,762 | ||||
Cost of operations | 52,564 | 46,943 | ||||||
Sales and marketing | 32,911 | 30,933 | ||||||
General and administrative | 23,781 | 23,534 | ||||||
Depreciation and amortization | 7,328 | 6,853 | ||||||
Interest income | 15 | 21 | ||||||
Interest expense | 6,172 | 5,832 | ||||||
|
|
|
| |||||
Income (loss) before income income tax provision | 11,091 | (1,312 | ) | |||||
Income tax provision | 4,825 | 226 | ||||||
|
|
|
| |||||
Net income (loss) | $ | 6,266 | $ | (1,538 | ) | |||
|
|
|
| |||||
Net income (loss) per common share: | ||||||||
Basic | $ | 0.16 | $ | (0.03 | ) | |||
|
|
|
| |||||
Diluted | $ | 0.15 | $ | (0.03 | ) | |||
|
|
|
| |||||
Weighted-average shares outstanding used in computing income (loss) per common share: | ||||||||
Basic | 39,268 | 49,007 | ||||||
|
|
|
| |||||
Diluted | 41,852 | 49,007 | ||||||
|
|
|
|
WEBMD HEALTH CORP.
CONSOLIDATED SUPPLEMENTAL FINANCIAL INFORMATION
(In thousands, unaudited)
Three Months Ended March 31, | ||||||||
2014 | 2013 | |||||||
Revenue | ||||||||
Public portal advertising and sponsorship | $ | 109,203 | $ | 93,438 | ||||
Private portal services | 24,629 | 19,324 | ||||||
|
|
|
| |||||
$ | 133,832 | $ | 112,762 | |||||
|
|
|
| |||||
Earnings before interest, taxes, non-cash and other items (“Adjusted EBITDA”) (a) | $ | 33,266 | $ | 21,289 | ||||
Interest, taxes, non-cash and other items (b) | ||||||||
Interest income | 15 | 21 | ||||||
Interest expense | (6,172 | ) | (5,832 | ) | ||||
Income tax provision | (4,825 | ) | (226 | ) | ||||
Depreciation and amortization | (7,328 | ) | (6,853 | ) | ||||
Non-cash stock-based compensation | (8,690 | ) | (9,937 | ) | ||||
|
|
|
| |||||
Net income (loss) | $ | 6,266 | $ | (1,538 | ) | |||
|
|
|
|
(a) | See Annex A-Explanation of Non-GAAP Financial Measures. |
(b) | Reconciliation of Adjusted EBITDA to net income (loss). |
WEBMD HEALTH CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
March 31, 2014 | December 31, 2013 | |||||||
(unaudited) | ||||||||
Assets | ||||||||
Cash and cash equivalents | $ | 778,401 | $ | 824,880 | ||||
Accounts receivable, net | 134,241 | 124,232 | ||||||
Prepaid expenses and other current assets | 12,544 | 13,243 | ||||||
Deferred tax assets | 13,588 | 13,620 | ||||||
|
|
|
| |||||
Total current assets | 938,774 | 975,975 | ||||||
Property and equipment, net | 62,151 | 64,884 | ||||||
Goodwill | 202,980 | 202,980 | ||||||
Intangible assets, net | 13,266 | 13,834 | ||||||
Deferred tax assets | 38,649 | 38,802 | ||||||
Other assets | 28,144 | 29,153 | ||||||
|
|
|
| |||||
Total Assets | $ | 1,283,964 | $ | 1,325,628 | ||||
|
|
|
| |||||
Liabilities and Stockholders’ Equity | ||||||||
Accrued expenses | $ | 54,910 | $ | 73,739 | ||||
Deferred revenue | 99,638 | 85,148 | ||||||
Liabilities of discontinued operations | 1,506 | 1,506 | ||||||
|
|
|
| |||||
Total current liabilities | 156,054 | 160,393 | ||||||
2.25% convertible notes due 2016 | 252,232 | 252,232 | ||||||
2.50% convertible notes due 2018 | 400,000 | 400,000 | ||||||
1.50% convertible notes due 2020 | 300,000 | 300,000 | ||||||
Other long-term liabilities | 21,673 | 22,103 | ||||||
Stockholders’ equity | 154,005 | 190,900 | ||||||
|
|
|
| |||||
Total Liabilities and Stockholders’ Equity | $ | 1,283,964 | $ | 1,325,628 | ||||
|
|
|
|
WEBMD HEALTH CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands, unaudited)
Three Months Ended March 31, | ||||||||
2014 | 2013 | |||||||
Cash flows from operating activities: | ||||||||
Net income (loss) | $ | 6,266 | $ | (1,538 | ) | |||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 7,328 | 6,853 | ||||||
Non-cash interest, net | 1,128 | 1,082 | ||||||
Non-cash stock-based compensation | 8,690 | 9,937 | ||||||
Deferred income taxes | 201 | (99 | ) | |||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | (10,009 | ) | 4,809 | |||||
Prepaid expenses and other, net | 210 | (193 | ) | |||||
Accrued expenses and other long-term liabilities | (20,401 | ) | (14,850 | ) | ||||
Deferred revenue | 14,490 | 5,044 | ||||||
|
|
|
| |||||
Net cash provided by operating activities | 7,903 | 11,045 | ||||||
Cash flows from investing activities: | ||||||||
Purchases of property and equipment | (5,533 | ) | (2,876 | ) | ||||
|
|
|
| |||||
Net cash used in investing activities | (5,533 | ) | (2,876 | ) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from exercise of stock options | 17,482 | 672 | ||||||
Cash used for withholding taxes due on stock-based awards | (5,326 | ) | (174 | ) | ||||
Purchases of treasury stock | (65,052 | ) | (1,281 | ) | ||||
Excess tax benefit on stock-based awards | 4,047 | — | ||||||
|
|
|
| |||||
Net cash used in financing activities | (48,849 | ) | (783 | ) | ||||
|
|
|
| |||||
Net (decrease) increase in cash and cash equivalents | (46,479 | ) | 7,386 | |||||
Cash and cash equivalents at beginning of period | 824,880 | 991,835 | ||||||
|
|
|
| |||||
Cash and cash equivalents at end of period | $ | 778,401 | $ | 999,221 | ||||
|
|
|
|